# (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

> **NCT00679432** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 510 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **PROCEDURE:** Blood sampling, endoscopy
- **DRUG:** budesonide-MMX® 6 mg
- **DRUG:** budesonide-MMX® 9 mg
- **DRUG:** Placebo
- **DRUG:** Asacol® 400 mg

## Key facts

- **NCT ID:** NCT00679432
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2019-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679432, "(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00679432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*